“Laughing All the Way to the Bank: Vertex’s Q4 Earnings Take a Dip, But Revenue Still Sparkles”
Vertex’s Earnings Expectation and Revenue Growth There is speculation in the market about the decline in Vertex’s earnings, but the good news is that double-digit revenue growth is expected to continue. This growth can be attributed to the newly approved non-opioid drug JOURNAVX and the expansion of the cystic fibrosis (CF) franchise. JOURNAVX: A Game…